Investigation Of Receptivity Markers For Endometrial Cancer Treatment Development

NCT05914844 | Completed

• 1 other identifier: MCBU_endometriumcancer
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Hyaluronan is an extracellular matrix protein that is involved in cell-cell and cell-matrix interactions. Hyaluronan performs this activity through hyaladherins, which are intracellular and extracellular receptors. The purpose of this study was to compare the distributions of Hyaluronan Synthetase 2 (HAS2) and CD44s in healthy endometrial tissue samples obtained during the proliferative phase endometrium (PPE) and secretory phase endometrium (SPE), as well as pathologic samples diagnosed with benign endometrial hyperplasia (EH), endometrial intraepithelial neoplasia (EIN), early stage of endometrial carcinoma (EC) (stage I/II) and advanced stage of endometrial carcinoma (stage III/IV) (n:5, each). By using the avidin-biotin-peroxidase method, tissue samples that had been fixed with formalin passed through a regular paraffin follow-up protocol, and subsequently embedded in paraffin were stained indirectly with anti-CD44s and anti-HAS2 primary antibodies. Immunostaining intensity was graded as 0: negative, 1: weak, 2: moderate, 3: strong, and 4: very strong using a semiquantitative technique. The ANOVA test was used to assess the statistical significance of the findings. Statistical significance was defined as (p) values less than 0.05. While weak HAS2 and weak/moderate CD44s immunoreactivity was observed on the surface epithelium (SE)/glandular epithelium (GE) and stroma of the tissue samples acquired during PPE; weak/moderate HAS2 and moderate CD44s immunoreactivity were observed in SPE and EH groups; moderate/strong HAS2, strong CD44s immunoreactivity was observed in EIN; strong/very strong HAS2 and very strong CD44s immunoreactivity were observed in early-stage EC and advanced stage EC. It was determined that the immunoreactivity intensity increased at a statistically significant level in both early and advanced stage EC. The fact that HAS2 and CD44s, two intracellular receptors, have increased in endometrial carcinoma leads us to believe that they are likely to play a role in tumor development, invasion, migration, metastasis and that they may be useful in developing future treatment protocols targeting hyaluronan receptors.

Conditions

Endometrial Cancer Stage

Keywords

endometrial carcinoma; immunohistochemistry; CD44s; HAS2

Outcome Measures

Primary Outcomes (1)

• Investigation Of Receptivity Markers For Endometrial Cancer Treatment Development

  The increase or decrease of hyaluronan receptors, which play a role in endometrial cancer, has a critical role to be explained in cancer treatments.

  Baseline

Study Arms (6)

Group 1:

Proliferative phase endometrium (PPE)

Group 2:

Secretory phase endometrium

Group 3:

Benign endometrial hyperplasia

Group 4:

Endometrial intraepithelial neoplasia

Group 5:

Early stage of endometrial carcinoma

Group6:

Advanced stage of endometrial carcinoma

Eligibility Criteria

• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with endometrium cancer

You may qualify if:

• \- All patients with endometrial carcinoma underwent surgery.

You may not qualify if:

• No patient was subject to chemotherapy or radiotherapy prior to surgery.

Sponsors & Collaborators

• Celal Bayar University: lead

Study Sites (1)

Manisa Celal Bayar University

Yunusemre, Mani̇sa, 45030, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITH DNA

endometrial tissue cells

MeSH Terms

Conditions

Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Asistant Prof.

Study Record Dates

• First Submitted: December 2, 2022
• First Posted: June 22, 2023
• Study Start: November 19, 2021
• Primary Completion: August 17, 2022
• Study Completion: February 1, 2023
• Last Updated: June 22, 2023

Record last verified: 2023-06

Locations

TU (1)